Synthetic peptide amides

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Reexamination Certificate

active

07727963

ABSTRACT:
The invention relates to synthetic tetrapeptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450CYP inhibition and low penetration into the brain. An exemplary synthetic tetrapeptide amide of the invention is D-Phe-D-Phe-D-Leu-(ε-Me) D-Lys-[4-Amidinohomopiperazine amide]:Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.

REFERENCES:
patent: 5965701 (1999-10-01), Junien et al.
patent: 6191103 (2001-02-01), Shohet et al.
patent: 6780846 (2004-08-01), O'Mahony et al.
patent: 6984719 (2006-01-01), Chemtob et al.
patent: 7402564 (2008-07-01), Schteingart et al.
patent: 2005/0113294 (2005-05-01), Dolle
patent: 2006/0229252 (2006-10-01), Falla et al.
patent: 43 10643 (1993-04-01), None
patent: 0 249 169 (1987-06-01), None
patent: 0 334 244 (1989-03-01), None
patent: 0 342 962 (1989-05-01), None
patent: 0 361 977 (1989-09-01), None
patent: 0 505 680 (1992-01-01), None
patent: 0 517 589 (1996-12-01), None
patent: 0 503 301 (1997-11-01), None
patent: WO 88/08429 (1988-11-01), None
patent: WO 94/21242 (1994-09-01), None
patent: WO 95/00546 (1995-01-01), None
patent: WO 95/22557 (1995-08-01), None
patent: WO 96/02267 (1996-01-01), None
patent: WO 97/07130 (1997-02-01), None
patent: WO 97/09995 (1997-03-01), None
patent: WO 98/08492 (1998-03-01), None
patent: WO 98/08868 (1998-03-01), None
patent: WO 99/21877 (1999-05-01), None
patent: WO 99/32510 (1999-07-01), None
patent: WO 03/011896 (2003-01-01), None
patent: WO 2006/058539 (2006-06-01), None
patent: WO 2006/058539 (2006-06-01), None
Vippagunta, et al. “Crystalline solids,” Adv. Drug Delivery Rev., 2001, 48, 3-26.
Byrn et al. (Solid State Chemistry of Drugs, 2 Ed. 1999 “Hydrates and Solvates” pp. 233-247.
Testa “Prodrug research: futile or fertile?” Biochemical Pharmacology, 2004, 68, 2097-2106.
Bentley, G.A. et al., Evidence for an action of morphine and the enkephalins on sensory nerve endings in the mouse peritoneum, Br. J. Pharmac., 73:325-332 (1981).
Diop, Laurent et al., Peripheral k-opioid receptors mediate the antinociceptive effect of fetodozine on the duodenal pain reflex in rat, European Journal of Pharmacology 271, pp. 65-71 (1994).
Iyer, S. et al., Characterization and Biological Significance of Immunosuppressive Peptide D2702.75-84 (E→V) Binding Protein, J. Biol. Chem., vol. 273, No. 5, pp. 2692-2697 (1998).
Junien and Riviere, Review article: the hypersensitive gut—peripheral kappa agonists as a new pharmacological approach, Alimentary Pharmacology and Therapeutics, 9:117-126 (1995).
Lamb, J.R. et al., Influence of antigen structure on the activation and induction of unresponsiveness in cloned human T lymphocytes, Immunology, 57, pp. 331-335 (1986).
Ostergaard, S. et al., Novel avidin and streptavidin biding sequences found in synthetic peptide libraries, FEBS Letters, 362, pp. 306-308 (1995).
Riviere, Pierre J.M. et al., Fedotozine Reverses Ileus Induced by Surgery or Peritonitis: Action at Peripheralκ-Opioid Receptors, Gastroenterology 104:724-731 (1993).
Samson, Isabelle et al., Screening a Random Pentapeptide Library, Composed of 14 D-Amino Acids, against the COOH-terminal Sequence of Fructose-1,6-bisphosphate Aldolase fromTrypanosoma brucei, The Journal of Biological Chemistry, vol. 272, No. 17, Issue Apr. 25, pp. 11378-11383 (1997).
Schröder, E., Syntheses des all-D-Val5-Angiotensin II-Asp1-β-amids, J. Liebigs Ann Chem, pp. 241-245 (1966).
Seo, Jeong Kon et al., A Peptide with Unique Receptor Specificity, Jimmunol, pp. 1895-1901 (1997).
Vanderah, T.W. et al., Mediation of Swim-Stress Antinociception by the Opioid Delta2Receptor in the Mouse1, J. Pharm. Exper. Therapeutics, vol. 262:1 (1992).
Vippagunta et al. “Crystalline solids” Adv. Drug Delivery Rev., 2001, 48, 2-26.
Vogler, von K. et al., Synthese von All-D-Val5-Angiotensin II-Asp1-β-Amid1), Helv Chim Acta, 48:6:152, pp. 1407-1414 (1965).
Vonvoigtlander, P.F. et al., U-50,488: A Selective and Structurally Novel Non-Mu (Kappa) Opioid Agonist, J. Pharm. Exper. Therapeutics, 224:7-12 (1983).
Wang, X. et al., Applications of topologically segregated bilayer beads in ‘one-bead one-compound’ combinatorial libraries, J. Peptide Res. 65, pp. 130-138 (2005).
Wisniewski, K. et al., Long Acting, Selective, Peripheral Kappa Agonists, J. Peptide Sci., 6 supp:S189 (2002) (Abstract).
Wisniewski, K. et al., Long Acting, Selective, Peripheral Kappa Agonists, Posters:1 Bioactive, P358 (Poster), 2000.
Wisniewski, K. et al., Long Acting, Selective, Peripheral Kappa Agonists, Peptides 2000:Proc. Of 36thEur Peptide Symp. (J. Martinez & J.A. Fehrentz, eds.) Editions EDK, pp. 775-776 (2001) (Mini-publication).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Synthetic peptide amides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Synthetic peptide amides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic peptide amides will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4249321

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.